Introduction
There is an urgent need for treatments to arrest structural progression in osteoarthritis (OA).
However, we lack responsive measures (biomarkers) which could be used in early phase evaluation of investigational therapies. Radiography and magnetic resonance imaging (MRI) offer many structural biomarkers, but currently these require larger sample sizes and longer duration of treatment than would be ideal in a Phase 2 study.
Bone is integral to the OA pathological process and a number of bony pathologies including subchondral bone thickening, trabecular morphometry, bone marrow lesions and bone shape have been investigated (1) . There is likely to be considerable interplay between the subchondral bone and cartilage (2). Changes in bone shape and area have been shown to be predictive biomarkers for the onset of knee osteoarthritis (3, 4) , and can be accurately quantified using active appearance modelling (AAM), a form of statistical shape modelling that enables automatic segmentation.( Figure   1 ) (5, 6) . Recent studies in large cohorts have shown that change in 3D bone area is specific for knee OA and more responsive than radiographic joint space width and cartilage thickness (7).
A previous study designed to assess the responsiveness of cartilage thickness in a small knee OA cohort enriched for known risk factors of progression including high BMI, female gender and varus alignment demonstrated no significant change in cartilage thickness at the group level in the medial femur or tibia at 3 or 6 months (8). The current post-hoc study analysed the changes in bone area of the femoral condyles in this cohort to determine the responsiveness of this novel bone biomarker.
Materials and Methods
29 participants were recruited in a multi-centre, non-randomized, observational cohort study at four sites in the USA (8 A single knee was selected, being the knee with highest KL score, or the right knee if no difference.
MR images were acquired using 3T Siemens systems, using the dual echo steady state water excitation acquisition sequence (DESS-we), previously used in the Osteoarthritis Initiative (9) . MR images were acquired at recruitment, with follow-up images at 1 week (providing a double baseline), 3 and 6 months. Ethics approval was obtained from the sites involved in the study and all participants gave informed consent.
Images were automatically segmented using AAMs of the femur, built using an unrelated training set (7) , which has been shown to segment with point-to-surface accuracy of less than 1mm (10) . Two area measures (mm 2 ) were extracted from the bone surface produced by the AAM: the medial and lateral femorotibial regions of the femur (Figure 1 ), which were found to be the most responsive regions in a larger study (7) .
Repeat baseline MRI scans were acquired a week apart (8) , allowing estimation of repeatability by calculation of root-mean-square coefficients of variation (CoV), and smallest detectable difference (SDD), defined as the mean of the differences ±1.96 standard deviations. Change over time was assessed using a paired t-test of the ratio of the value of each timepoint against the baseline value, using the geometric mean of the 2 baseline images. Spatial location of bone area change was visualised by colour change maps, and displayed on the mean bone shape (Figure 2 ).
Results
The mean age was 62 years (range 50 -80 greater than the SDD) with time, but progressors outnumbered regressors at each point. 41% of subjects progressed more than SDD using the MF bone area measure at 6 months (11 subjects), compared with 15% who lost cartilage greater than SDD in the MT region (4 subjects).
The spatial pattern of change was similar to that reported in a larger study (7) . Increase in area was seen in articulating tibiofemoral surfaces, together with a circumferential increase in bone area around the cartilage plate, in the osteophytic region ( Figure 2 ).
Discussion
In this small, short-term study of people with OA knee selected for high risk of structural progression, 3D bone area using AAMs demonstrated change in 3 months for the medial femoral region, and for both femoral regions at 6 months. Previous analysis of this dataset did not Though the participant numbers were small in this study, the change shows a clear trend in bone area change, with 3-month change about half that at 6 months. Rates of area change per bone region were also similar to those reported from a large OA longitudinal dataset, which showed annual change of 0.75% in the MF region, as compared to 1.2% in this study (3), further supporting the validity of these findings.
The structural endpoints in most clinical trials in the musculoskeletal area, such as those for rheumatoid arthritis where good treatments and patient responses are common, are driven by a few percent of progressors (change greater than SDD) because of the relationship between small changes and large measurement noise This study is notable, both because significant change is detected in the population, but also because the change shows a clear trend with time, and is greater than SDD in a significant number of participants.
Power calculations, using an SRM of 0.85, the value for change in MF region at 6 months, assuming intervention had 50% reduction, one-sided, 80% power, L=0.05%, show that cohorts of ~80 persons would be needed for each arm of an intervention study.
Longitudinal change in bone area has been reported elsewhere (12, 13) . These studies have primarily considered tibial rather than femoral bone, and use 2D methods of identification of area.
The repeatability of AAMs resulted in an SDD of approximately 1% compared to 4% in these previous studies.
There are limitations to this work. It is reasonable to expect that there may be some relationship between changes in bone and cartilage, but no relationship was seen in this admittedly small study.
While this analysis was based on an appropriately collected, well designed study, it does represent a post-hoc analysis. The MRI scanners and imaging sequences employed in this study were as used in 
Introduction
However, we lack responsive measures (biomarkers) which could be used in the early phase evaluation of investigational therapies. Radiography and magnetic resonance imaging (MRI) offer many structural biomarkers of structural change, but currently these require larger sample sizes and longer duration of treatment than would be ideal in a Phase 2 study of an investigational therapy.
Bone is integral to the OA pathological process and a number of bony pathologies including subchondral bone thickening, trabecular morphometry, bone marrow lesions and bone shape have been investigated (1) . There is likely to be considerable interplay between the subchondral bone and cartilage (2). Changes in bone shape and area have been shown to be predictive biomarkers for the onset of knee osteoarthritis (3, 4) , and can be accurately quantified using active appearance modelling (AAM), a form of statistical shape modelling that enables automatic segmentation. (Figure   1 ) (5, 6) . Recent studies in large cohorts have shown that change in 3D bone area is specific for knee OA and more responsive than radiographic joint space width and cartilage thickness (7).
Materials and Methods
29 participants were recruited in a multi-centre, non-randomized, observational cohort study at four sites in the USA (8) . 27 females had knee pain, a body mass index (BMI) ≥ 25 kg/m 2 , radiographic evidence of medial OA, and varus malalignment, and images at all timepoints, 2 did not have all MR images were acquired using 3T Siemens systems, using the dual echo steady state water excitation acquisition sequence (DESS-we), as previously used in the Osteoarthritis Initiative (9) . MR images were acquired at recruitment, with follow-up images at 1 week (providing a double baseline), 3 months and 6 months. Ethics approval was obtained from the sites involved in the study and all participants gave informed consent.
Images were automatically segmented using AAMs of the femur, built using an unrelated training set (7), which has been shown to segment with point-to-surface accuracy of less than 1mm (10) . Two area measures (mm 2 ) were extracted from the triangulated bone surface produced by the AAM: the medial and lateral femorotibial regions of the femur (Figure 1 ), which were found to be the most responsive regions in a larger study (7) .
In the original imaging of participants,R repeat baseline MRI scans were acquired a week apart (8), allowing estimation of repeatability by calculation of root-mean-square coefficients of variation (CoV), and smallest detectable difference (SDD), defined as the mean of the differences ±1.96 standard deviations. Change over time was assessed using a paired t-test of the ratio of the value of each timepoint against the baseline value, using either the geometric mean of the 2 baseline images.
The sSpatial location of bone area change was visualised by colour change maps, and displayed on the mean bone shape (Figure 2 ).
Results
The mean age was 62 years (range 50 -80). Mean BMI at baseline was 35 kg/m 2 (range 31 -44); mean WOMAC pain score was 7 (range 1-12). Mean knee alignment was 0.4° (range -1.9° to +6.3°) (varus positive);, and 12 of 27 were left knees. 19 knees were Kellgren Lawrence Grade 3; the remainder were Grade 2. Graphs of change with time for each participant are shown in Figure 3 , together with the SDD for each measure. Bone area measures showed increasing numbers of progressors (those with change greater than the SDD) with time, but progressors outnumbered regressors at each point. 41% of subjects progressed more than SDD using the MF bone area measure at 6 months (11 subjects), compared with 15% who lost cartilage greater than SDD in the MT region (4 subjects).
The spatial pattern of change was similar to that reported in a larger study (7) . Increase in area was seen in articulating tibiofemoral surfaces, together with a circumferential increase in bone area around the cartilage plate, in the osteophytic region (Figure 2 ). In this small, short-term study of people with OA knee selected for high risk of structural progression, 3D bone area using AAMs demonstrated change in 3 months for the medial femoral region, and for both femoral regions at 6 months. Previous analysis of this dataset did not demonstrate significant change in cartilage thickness (1), one of the most promising MRI biomarkers of OA progression to date (11) .
Discussion
Though the participant numbers were small in this study, the change shows a clear trend in bone area change, with the 3-month change about half that at 6 months. Rates of area change per bone region were also similar to those reported from a large OA longitudinal dataset, which showed annual change of 0.75% in the MF region, as compared to 1.2% in this study (3) , further supporting the validity of these findings.
The structural endpoints in most clinical trials in the musculoskeletal area, such as those for rheumatoid arthritis where good treatments and patient responses are common, are driven by a few percent of progressors (those change greater than SDD) because of the relationship between small changes and large measurement noise. In such trials, it is uncommon for the mean change of the population to exceed the SDD. This study is notable, both because significant change is detected in the population, but also because the change shows a clear trend with time, and is measurable greater than SDD in a significant number of participants.
The repeatability of AAMs resulted in an SDD of approximately 1% compared to 4% in these previous studies. There are limitations to this work. It is reasonable to expect that there may be some relationship between changes in bone and cartilage, but no relationship was seen in this admittedly small study.
While this analysis was based on an appropriately collected, well designed study, it does represent a post-hoc analysis. The MRI scanners and imaging sequences employed in this study were as used in the Osteoarthritis Initiative (9) . The images derived from these MRI scans were not optimised to visualise bone, so further responsiveness may be possible with dedicated bone sequences. We have only provided data on one 3D bone shape biomarker (bone area) and other measures, such as those that measure other specific sites of changeregions within the subchondral bone, may be more informativeresponsive.
This study compared bone area with one specific method of cartilage measurement; other methods, and other variables such as volume may provide better responsiveness. However, we are not aware of any method showing significant cartilage change in less than 30 people in 6 months.
In this small cohort selected for high risk of OA progression, bone area changed in an approximately linear manner at 3 and 6 months from baseline. Bone area shows promise as a highly sensitive biomarker of OA progression, detecting change when current imaging outcomes are unable to do so, and provides a potential tool for small, short-duration, proof of concept studies, such as those with a treatment likely to affect bone. 
